Professor, Dr. Naoki Yamamoto is employed at the Center for Society-Academia Collaboration/International Center for Cell and Gene Therapy, Research Promotion Headquarters, Fujita Health University. He graduated from Fujita Health University in 1994, worked at Fujita Health University Hospital and Emergency Center in 1996, and obtained a Doctorate (Medicine) at the Fujita Health University Graduate School in 2002. Subsequently, he worked at the Joint Research Laboratory at Fujita Health University in 2004 and at Regenerative Medicine Promotion Facility at Fujita Medical University in 2018 as an Associate Professor. Thereafter, he worked at the Department of Ophthalmology, School of Medicine, Kanazawa Medical University in 2020, and has been employed in his current position since 2021. In the field of cell biology, he has established new cell culture methods for iPS cells, tissue stem cells, and cancer cells, aiming at clinical application using basic research.
Research Keywords & Expertise
Histopathology
Ophthalmology
Regenerative Medicine
Molecular cell biology
iPS cells
Immortalized cells
Fingerprints
12%
Regenerative Medicine
12%
iPS cells
7%
Ophthalmology
5%
Histopathology
Short Biography
Professor, Dr. Naoki Yamamoto is employed at the Center for Society-Academia Collaboration/International Center for Cell and Gene Therapy, Research Promotion Headquarters, Fujita Health University. He graduated from Fujita Health University in 1994, worked at Fujita Health University Hospital and Emergency Center in 1996, and obtained a Doctorate (Medicine) at the Fujita Health University Graduate School in 2002. Subsequently, he worked at the Joint Research Laboratory at Fujita Health University in 2004 and at Regenerative Medicine Promotion Facility at Fujita Medical University in 2018 as an Associate Professor. Thereafter, he worked at the Department of Ophthalmology, School of Medicine, Kanazawa Medical University in 2020, and has been employed in his current position since 2021. In the field of cell biology, he has established new cell culture methods for iPS cells, tissue stem cells, and cancer cells, aiming at clinical application using basic research.